MARKET

INTI

INTI

Inhibitor Therap
OTCMQB
0.089
NaN%
Closed 09:30 09/11 EDT
OPEN
--
PREV CLOSE
0.089
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.150
52 WEEK LOW
0.040
MARKET CAP
15.47M
P/E (TTM)
-4.6597
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Inhibitor Therapeutics Highlights -2-
Dow Jones · 3d ago
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
Barchart · 3d ago
Tilaknagar Industries Sets AGM Date and Dividend Record Date for FY 2025-26
TipRanks · 08/31 19:33
Tilaknagar Industries Revises Vesting Timeline for ESOP 2025 Grants
TipRanks · 08/26 18:24
Tilaknagar Industries shareholders back reappointment of director via postal ballot
TipRanks · 08/24 12:18
Based on the provided financial report articles, I generated the title for the article: "INTI's Q2 2026 Financial Report: Series A Preferred Stock, Series B Convertible Preferred Stock, and Undesignated Preferred Stock Disclosures" Please note that the title may not be exact, as the provided text is a financial report and may not contain a clear title.
Press release · 08/15 08:20
Tilaknagar Industries Hits Record Volumes as Imperial Blue Leads Deluxe Whisky Segment
TipRanks · 08/04 06:53
Tilaknagar Industries Opens Special Window for Re-Lodgement of Physical Share Transfers
TipRanks · 07/09 06:38
More
About INTI
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Webull offers Inhibitor Therapeutics Inc stock information, including OTCMQB: INTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTI stock methods without spending real money on the virtual paper trading platform.